Long-term follow-up of liver disease outcomes in adults with fatty liver
Follows adults with fatty liver disease over several years to study outcomes.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
Key facts
- Where
- Turin, ItalySee the site
Where in Italy
- Division of Gastroenterology, Department of Medical Sciences, University of TurinTurin, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universität des Saarlandes
- Trial code
- NCT06907563
- Record updated
- 2 April 2025
- Original description
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.Read full original descriptionShow less
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.
Inclusion: Previous Informed consent for cohort studies; > 18 years of age; Diagnosis of SLD (MASLD, MetALD, ALD).
Exclusion: No consent for previous cohort studies; < 18 years of age; No Diagnosis of SLD (MASLD, MetALD, ALD).